The impact of motility on lymphoma presentation and dissemination

运动性是免疫细胞的内在特征。恶性淋巴瘤来源于B或T细胞，通常与它们的起源细胞相似。最近，在细胞内信号级联的表征方面取得了巨大的进展，当细胞移动时发生。有趣的是，促进运动的细胞内因子与T细胞受体途径的下游信号传导因子部分重叠。T细胞淋巴瘤特别显示运动相关基因的体细胞突变。在这个项目中，我们希望将分子生物学和更多应用的临床病理学方法结合起来，以了解恶性淋巴瘤运动的影响。我们先前在研究间变性大细胞淋巴瘤和经典霍奇金淋巴瘤细胞系的运动性时观察到了令人惊讶的差异。现在，我们的目标是揭示为什么特定的淋巴瘤实体的淋巴瘤细胞的运动性彼此不同，并找到一个机制解释这种现象。我们特别要关注T细胞淋巴瘤中的间变性大细胞淋巴瘤和血管免疫母细胞性淋巴瘤，同时也将经典型霍奇金淋巴瘤与其他B细胞淋巴瘤进行比较研究，以获得更全面的认识。我们将研究淋巴瘤细胞系和原发性淋巴瘤细胞在transwell小室、3D胶原凝胶、不同类型的微通道以及新鲜淋巴结/扁桃体厚切片中的运动性。我们将使用基因修饰和未修饰的细胞系，并将扩大我们的理解，通过比较RNA测序和蛋白质组学技术的运动和非运动细胞群体。更全面的分子迁移模式的恶性淋巴瘤的理解将有助于更好地了解这些疾病的病理生理和传播模式，并可能是第一步意味着运动的预后和治疗。

Motility is an intrinsic feature of immune cells. Malignant lymphomas derive from B or T cells and usually resemble their cells of origin. Recently, tremendous advances in the characterization of intracellular signaling cascades, that take place when a cell moves, were achieved. Interestingly, the intracellular factors that promote motility partly overlap with downstream signaling factors of the T-cell receptor pathway. T-cell lymphomas in particular show somatic mutations in motility-related genes. In this project we want to bring together molecular biological and more applied clinicopathological approaches to learn about the impact of motility in malignant lymphomas. We previously observed surprising differences when studying the motility of anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines. Now we aim to reveal why specific lymphoma entities differ from each other by the motility of the lymphoma cells and to find a mechanistic explanation for this phenomenon. We particularly want to focus on the T-cell lymphomas anaplastic large cell lymphoma and angioimmunoblastic lymphoma, but will also study classical Hodgkin lymphoma and other B-cell lymphomas for comparison to obtain a more comprehensive understanding. We will study the motility of lymphoma cell lines and primary lymphoma cells in transwell chambers, 3D collagen gels, different types of microchannels as well as in thick slices of fresh lymph nodes/tonsils. We will use genetically modified and unmodified cell lines and will enlarge our understanding by comparative RNA sequencing and proteomic technologies of motile and non-motile cell populations. A more comprehensive molecular understanding of the migration patterns of malignant lymphomas will contribute to a better understanding of the pathophysiology and dissemination patterns of these diseases and may be a first step implying motility in prognosis and treatment.